Since menin inhibitors are currently only in the early phases of clinical trials, extended follow-ups on individuals receiving menin inhibitors are necessary to determine whether these inhibitors have any meaningful effects on tumorigenesis in these tissues where menin serves a tumor suppressive role. Here, MEN1 is linked to neoplasm.